Scholar Rock HoldingSRRK
Recorded

Scholar Rock Holding UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Michael YeeSenior Biotechnology Analyst

Everyone, thank you for joining us on our next session here at the UBS Global Biopharma Conference. I'm Michael Yee, senior biotechnology analyst at UBS, and very thrilled to have up here the chairman and chief executive officer of Scholar Rock, David Hallal. It's great to have you here.

David HallalChairman and CEO

Great to be here with you, Mike.

Michael YeeSenior Biotechnology Analyst

Thank you so much. If you have any other questions that we can answer, we got the whole team here also with us at the front of the room. David, congratulations. Obviously, the approval and the launch of ISEMBYLD, I call it the anti-myostatin, apitegromab.

Michael YeeSenior Biotechnology Analyst

Right. I've been following this drug since it was pre-clinical, so we go way back, and I followed this story.

Michael YeeSenior Biotechnology Analyst

I'm still getting used to the name, ISEMBYLD.

Michael YeeSenior Biotechnology Analyst

Right. But maybe if you could just set the table for us.

Michael YeeSenior Biotechnology Analyst

Obviously, talk a little bit about the recent approval and specifically the early launch, because that is exactly where you guys are, an exciting time period for Scholar Rock. And maybe just set the table for that, and we will talk a little bit about the opportunity for ISEMBYLD.

David HallalChairman and CEO

Sure. Mike, you and I have both been around this story for a while.

David HallalChairman and CEO

Yes. I am in my 10th year now Okay at Scholar Rock, and we are gratified to be at this position of eight weeks post-U.S. approval for ISEMBYLD.

David HallalChairman and CEO

And we are very encouraged by our first eight weeks in the marketplace.

David HallalChairman and CEO

Okay. And look, there were a few dynamics for us that really laid groundwork for what we expect to be a very positive launch.

David HallalChairman and CEO

Okay. First and foremost was, as we have noted, the number one need in the 2026 Cure SMA survey amongst all SMA patients was muscle strength.

David HallalChairman and CEO

You combine that with three-quarters of neurologists have an appreciation that the future of treating SMA patients is by addressing both the motor neuron with SMN-targeted therapies and the muscle with an anti-myostatin, apitegromab, or as you and I now call it, ISEMBYLD. That is a nice setup for us. Secondly, the label. We were thrilled and gratified that the FDA recognized the breadth of patients that could benefit from ISEMBYLD therapy, and our approval covers all patients two years of age and older who are currently receiving an SMN2-targeted therapy. And we estimate that that is about 6,600 patients in the U.S. today.

Michael YeeSenior Biotechnology Analyst

A very broad label. That was an important thing.

David HallalChairman and CEO

Which we were very pleased to see. Then lastly, I would just say that this is an experienced marketplace. All 6,600 of those patients are on either Evrysdi, SPINRAZA, or HD SPINRAZA. So they and their healthcare teams, their physicians, are extremely experienced with the path to access and reimbursement. So that lays the groundwork quite nicely for us as we launched in mid-September to be able to start the process to generate demand for. We are pleased with both the volume and the breadth of demand so far.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day